Genmab (GMAB)
(Delayed Data from NSDQ)
$21.78 USD
+0.11 (0.51%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $21.78 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Genmab A/S Sponsored ADR has a PEG ratio of 7.46 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GMAB 21.78 +0.11(0.51%)
Will GMAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMAB
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Will Escalating Medical Costs Dampen Centene's Q2 Earnings?
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
Other News for GMAB
J&J says Darzalex injectable granted EU nod for smouldering multiple myeloma
Genmab (GMAB) Reports Strong Darzalex Sales in Q2 2025
J&J boosts full-year outlook on forex tailwinds and operational performance
Genmab reports Q2 Darzalex net sales of $3.54 billion
Genmab reports Q2 worldwide net sales of Darzalex $3.54B